These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1055 related items for PubMed ID: 32327243

  • 1. Development of de novo HLA donor specific antibodies (HLA-DSA), HLA antibodies (HLA-Ab) and allograft rejection post blood transfusion in kidney transplant recipients.
    Jalalonmuhali M, Carroll RP, Tsiopelas E, Clayton P, Coates PT.
    Hum Immunol; 2020 Jul; 81(7):323-329. PubMed ID: 32327243
    [Abstract] [Full Text] [Related]

  • 2. Shared alloimmune responses against blood and transplant donors result in adverse clinical outcomes following blood transfusion post-renal transplantation.
    Hassan S, Regan F, Brown C, Harmer A, Anderson N, Beckwith H, Roufosse CA, Santos-Nunez E, Brookes P, Taube D, Willicombe M.
    Am J Transplant; 2019 Jun; 19(6):1720-1729. PubMed ID: 30582278
    [Abstract] [Full Text] [Related]

  • 3. Incidences of preformed and de novo donor-specific HLA antibodies and their clinicohistological correlates in the early course of kidney transplantation.
    Huang Y, Ramon D, Luan FL, Sung R, Samaniego M.
    Clin Transpl; 2012 Jun; ():247-56. PubMed ID: 23721029
    [Abstract] [Full Text] [Related]

  • 4. Characteristics of donor-specific anti-HLA antibodies and outcome in renal transplant patients treated with a standardized induction regimen.
    Zecher D, Bach C, Staudner C, Böger CA, Bergler T, Banas B, Spriewald BM.
    Nephrol Dial Transplant; 2017 Apr 01; 32(4):730-737. PubMed ID: 28339671
    [Abstract] [Full Text] [Related]

  • 5. Association between longer hospitalization and development of de novo donor specific antibodies in simultaneous liver-kidney transplant recipients.
    Yazawa M, Cseprekal O, Helmick RA, Talwar M, Balaraman V, Podila PSB, Fossey S, Satapathy SK, Eason JD, Molnar MZ.
    Ren Fail; 2020 Nov 01; 42(1):40-47. PubMed ID: 31875761
    [Abstract] [Full Text] [Related]

  • 6. Evolution of donor-specific antibodies (DSA) and incidence of de novo DSA in solid organ transplant recipients after switch to everolimus alone or associated with low dose of calcineurin inhibitors.
    Perbos E, Juinier E, Guidicelli G, Dromer C, Merville P, Billes MA, Taupin JL, Neau-Cransac M.
    Clin Transplant; 2014 Sep 01; 28(9):1054-60. PubMed ID: 25040585
    [Abstract] [Full Text] [Related]

  • 7. Donor-specific HLA alloantibodies: Impact on cardiac allograft vasculopathy, rejection, and survival after pediatric heart transplantation.
    Tran A, Fixler D, Huang R, Meza T, Lacelle C, Das BB.
    J Heart Lung Transplant; 2016 Jan 01; 35(1):87-91. PubMed ID: 26422083
    [Abstract] [Full Text] [Related]

  • 8. Acute Rejection, Kidney Allograft Function, and Graft Survival in Patients with Circulating Pre-Transplant IgG Antibodies Directed Against Donor HLA-A, -B, or -C Locus Determined Antigens.
    Abuhelaiqa E, Friedlander R, Aull M, Putheti P, Sharma V, Suthanthiran M, Dadhania D.
    Clin Transpl; 2016 Jan 01; 32():83-91. PubMed ID: 28564525
    [Abstract] [Full Text] [Related]

  • 9. Clinical and anti-HLA antibody profile of nine renal transplant recipients with failed grafts: donor-specific and non-donor-specific antibody development.
    Rebellato LM, Ozawa M, Verbanac KM, Catrou P, Haisch CE, Terasaki PI.
    Clin Transpl; 2006 Jan 01; ():241-53. PubMed ID: 18365382
    [Abstract] [Full Text] [Related]

  • 10. Clinical significance of low pre-transplant donor specific antibodies (DSA) in living donor kidney recipients with negative complement-dependent cytotoxicity crossmatches (CDCXM), and negative flow cytometry crossmatches (FLXM) - A single-center experience.
    Olszowska-Zaremba N, Gozdowska J, Zagożdżon R.
    Transpl Immunol; 2022 Oct 01; 74():101672. PubMed ID: 35868613
    [Abstract] [Full Text] [Related]

  • 11. Non-HLA Antibodies and Epitope Mismatches in Kidney Transplant Recipients With Histological Antibody-Mediated Rejection.
    Crespo M, Llinàs-Mallol L, Redondo-Pachón D, Butler C, Gimeno J, Pérez-Sáez MJ, Burballa C, Buxeda A, Arias-Cabrales C, Folgueiras M, Sanz-Ureña S, Valenzuela NM, Reed EF, Pascual J.
    Front Immunol; 2021 Oct 01; 12():703457. PubMed ID: 34305943
    [Abstract] [Full Text] [Related]

  • 12. Impact of pretransplant donor-specific antibodies on kidney allograft recipients with negative flow cytometry cross-matches.
    Kwon H, Kim YH, Choi JY, Shin S, Jung JH, Park SK, Han DJ.
    Clin Transplant; 2018 Jun 01; 32(6):e13266. PubMed ID: 29676812
    [Abstract] [Full Text] [Related]

  • 13. Donor specific HLA antibodies & allograft injury: mechanisms, methods of detection, manifestations and management.
    McCaughan JA, Tinckam KJ.
    Transpl Int; 2018 Oct 01; 31(10):1059-1070. PubMed ID: 30062683
    [Abstract] [Full Text] [Related]

  • 14. Posttransplant de novo donor-specific hla antibodies identify pediatric kidney recipients at risk for late antibody-mediated rejection.
    Ginevri F, Nocera A, Comoli P, Innocente A, Cioni M, Parodi A, Fontana I, Magnasco A, Nocco A, Tagliamacco A, Sementa A, Ceriolo P, Ghio L, Zecca M, Cardillo M, Garibotto G, Ghiggeri GM, Poli F.
    Am J Transplant; 2012 Dec 01; 12(12):3355-62. PubMed ID: 22959074
    [Abstract] [Full Text] [Related]

  • 15. C1q-binding DSA and allograft outcomes in pediatric kidney transplant recipients.
    Hayde N, Solomon S, Caglar E, Ge J, Qama E, Colovai A.
    Pediatr Transplant; 2021 Mar 01; 25(2):e13885. PubMed ID: 33131194
    [Abstract] [Full Text] [Related]

  • 16. Clinical Relevance of Posttransplant DSAs in Patients Receiving Desensitization for HLA-incompatible Kidney Transplantation.
    Vo AA, Aubert O, Haas M, Huang E, Zhang X, Choi J, Peng A, Najjar R, Sethi S, Ammerman N, Lim K, Jordan SC.
    Transplantation; 2019 Dec 01; 103(12):2666-2674. PubMed ID: 30883456
    [Abstract] [Full Text] [Related]

  • 17. Pretransplant angiotensin II type 1-receptor antibodies are a risk factor for earlier detection of de novo HLA donor-specific antibodies.
    Cuevas E, Arreola-Guerra JM, Hernández-Méndez EA, Salcedo I, Castelán N, Uribe-Uribe NO, Vilatobá M, Contreras-Saldívar AG, Sánchez-Cedillo AI, Ramírez JB, de Rungs D, Granados J, Morales-Buenrostro LE, Alberú J.
    Nephrol Dial Transplant; 2016 Oct 01; 31(10):1738-45. PubMed ID: 27220757
    [Abstract] [Full Text] [Related]

  • 18. The Role of Donor-Specific Antibodies in Intestinal Transplantation: Experience at the University of California Los Angeles and Literature Review.
    Cheng EY, Kaneku H, Farmer DG.
    Clin Transpl; 2014 Oct 01; ():153-9. PubMed ID: 26281140
    [Abstract] [Full Text] [Related]

  • 19. Donor-specific anti-HLA antibodies with antibody-mediated rejection and long-term outcomes following heart transplantation.
    Clerkin KJ, Farr MA, Restaino SW, Zorn E, Latif F, Vasilescu ER, Marboe CC, Colombo PC, Mancini DM.
    J Heart Lung Transplant; 2017 May 01; 36(5):540-545. PubMed ID: 27916323
    [Abstract] [Full Text] [Related]

  • 20. Human Leukocyte Antigen Compatibility and De Novo Donor-Specific Antibodies in Long-term Renal Transplant Patients With Stable Graft Function.
    Kasimatis E, Fylaktou A, Karampatakis T, Schoina M, Zarras C, Anastasiou A, Papachristou M, Boukla A, Daoudaki M, Fouzas I, Papagianni A.
    Transplant Proc; 2019 Mar 01; 51(2):413-415. PubMed ID: 30879554
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 53.